Trevi Therapeutics, Inc.
TRVI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $416 | $133 | $125 | $18 |
| - Cash | $34 | $32 | $13 | $37 |
| + Debt | $1 | $1 | $9 | $15 |
| Enterprise Value | $383 | $102 | $121 | -$4 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$48 | -$29 | -$28 | -$33 |
| % Margin | – | – | – | – |
| Net Income | -$48 | -$29 | -$29 | -$34 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.47 | -0.29 | -0.45 | -1.49 |
| % Growth | -62.1% | 35.6% | 69.8% | – |
| Operating Cash Flow | -$38 | -$32 | -$28 | -$29 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$38 | -$32 | -$28 | -$29 |